Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-03-20
2007-03-20
Henley, II, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S471000
Reexamination Certificate
active
11154909
ABSTRACT:
Combinations of diuretics and vasopressin antagonists are useful to slow and reverse the symptoms and process of congestive heart failure, to increase the excretion of water in the urine, and to decrease the excretion of sodium and potassium ions in urine. Preferred vasopressin antagonists have the formulawherein R and R5are hydrogen or lower alkyl;R1, R2, and R3are hydrogen, halo, alkyl, alkoxy, and amino; andR4is hydrogen or phenyl, and a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 5225402 (1993-07-01), Ogawa et al.
patent: 5256687 (1993-10-01), Becker et al.
patent: 5258510 (1993-11-01), Hidenori et al.
patent: 5338755 (1994-08-01), Wagnon et al.
patent: 5719155 (1998-02-01), Cho et al.
patent: 5723606 (1998-03-01), Tanaka et al.
patent: 6420358 (2002-07-01), Ellis-Grosse et al.
patent: 0205334 (1986-12-01), None
patent: 0344995 (1989-12-01), None
patent: 0365134 (1990-04-01), None
patent: 0229329 (1993-07-01), None
patent: WO 98/25901 (1998-06-01), None
PCT International Search Report, PCT/US01/09265, date not available.
Chan, et al, “VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist”, Advances in Experimental Medicine and Biology, vol. 449, 1998 pp. 439-443.
Swan, et al, “Interaction between VPA-985, and ADH (V2) antagonist and furosemide”, Journal of the American Society of Nephrology, vol. 10, 1999, pp. 124A.
Taneja, et al, “Current status of acute intravenous therapy for chronic heart failure exacerbations”, Congestive Heart Failure, vol. 5, No. 5, 1999, pp. 199-207, 215.
Hirano, et al., “Effects of the V2-Receptor Antagonist OPC-41061 and the Loop Diuretic Forosemide Alone and in Combination in Rats”, The Journal of Pharmacology and Experimental Therapeutics, 2000, pp. 288-294, vol. 292(1).
Tammara, et al, Pharmacokinetic and Pharmacodynamic Interaction Between OPC-41061 Furosemide and Hydrochlorothiazide, date/source unavailable.
Bakker-Arkema Rebecca Guggemos
Pressler Milton Lethan
Astellas Pharma Inc.
Finnegan Henderson Farabow Garrett & Dunner LLP
Henley II Raymond J.
LandOfFree
Treatment of congestive heart failure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of congestive heart failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of congestive heart failure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3724804